Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.88% | 35.21% | 53.34% | -1,487.50% | 63.79% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.96% | 0.00% | -91.82% | 81.74% | -39.64% |
| Change in Net Operating Assets | 511.76% | -1,763.18% | -19.05% | -27.09% | -91.12% |
| Cash from Operations | -114.76% | -86,800.00% | -318.60% | -57.14% | 59.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 63.83% | -5.66% | 1,426.09% | -2,245.00% | 176.47% |
| Total Debt Repaid | -- | -- | 71.60% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 60.87% | 18,176.32% | 3,129.41% | -6,140.00% | -2.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 107.69% | -- | -- | -- | -- |
| Net Change in Cash | 104.00% | -187.50% | 888.89% | -2.08% | 89.32% |